These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 32509254)
21. A case of COVID-19-associated mucormycosis due to Lichtheimia ramosa. Aboutalebian S; Erami M; Momen-Heravi M; Charsizadeh A; Hezaveh SJH; Matini AH; Ahsaniarani AH; Fakhrehi M; Mirhendi H J Clin Lab Anal; 2023 Apr; 37(8):e24895. PubMed ID: 37183276 [TBL] [Abstract][Full Text] [Related]
22. Short intravenous amphotericin B followed by oral posaconazole using a simple, stratified treatment approach for diabetes or COVID-19-associated rhino-orbito-cerebral mucormycosis: a prospective cohort study. Manesh A; Devasagayam E; Bhanuprasad K; Varghese L; Kurien R; Cherian LM; Dayanand D; George MM; Kumar SS; Karthik R; Vanjare H; Peter J; Michael JS; Thomas M; Mathew BS; Samuel P; Peerawaranun P; Mukaka M; Rupa V; Varghese GM Clin Microbiol Infect; 2023 Oct; 29(10):1298-1305. PubMed ID: 37348653 [TBL] [Abstract][Full Text] [Related]
23. Surgical management of post-COVID invasive rhino-orbito-cerebral mucormycosis and its outcomes: Role of neurosurgeons in a tertiary care center. Das AK; Mani SK; Singh SK Surg Neurol Int; 2022; 13():335. PubMed ID: 36128146 [TBL] [Abstract][Full Text] [Related]
24. C-reactive Protein Kinetics During In-Patient Treatment of COVID-19-Associated Rhino-Orbito-Cerebral Mucormycosis: A Retrospective Cohort Study in a Tertiary Hospital in Central India. B H S; Bidkar V; Prathipati K; Dabhekar S; Selvaraj K; G D Cureus; 2024 Apr; 16(4):e59007. PubMed ID: 38800245 [TBL] [Abstract][Full Text] [Related]
25. Posaconazole: an emerging therapeutic option for invasive rhino-orbito-cerebral mucormycosis. Manesh A; John AO; Mathew B; Varghese L; Rupa V; Zachariah A; Varghese GM Mycoses; 2016 Dec; 59(12):765-772. PubMed ID: 27443253 [TBL] [Abstract][Full Text] [Related]
26. Fatal strokes in patients with rhino-orbito-cerebral mucormycosis and associated vasculopathy. Thajeb P; Thajeb T; Dai D Scand J Infect Dis; 2004; 36(9):643-8. PubMed ID: 15370650 [TBL] [Abstract][Full Text] [Related]
29. Unilateral rhino-orbital-cerebral mucormycosis with contralateral endogenous fungal endophthalmitis. Ho HC; Liew OH; Teh SS; Hanizasurana H; Ibrahim M; Shatriah I Clin Ophthalmol; 2015; 9():553-6. PubMed ID: 25848206 [TBL] [Abstract][Full Text] [Related]
30. Rhino-orbital-cerebral mucormycosis (ROCM) and associated cerebritis treated with adjuvant retrobulbar amphotericin B. Safi M; Ang MJ; Patel P; Silkiss RZ Am J Ophthalmol Case Rep; 2020 Sep; 19():100771. PubMed ID: 32551404 [TBL] [Abstract][Full Text] [Related]
31. Outcomes and factors affecting them in patients with rhino-orbito-cerebral mucormycosis. Kashkouli MB; Abdolalizadeh P; Oghazian M; Hadi Y; Karimi N; Ghazizadeh M Br J Ophthalmol; 2019 Oct; 103(10):1460-1465. PubMed ID: 30514712 [TBL] [Abstract][Full Text] [Related]
32. Rhino-orbito-cerebral mucormycosis: report of two cases and review of the literature. Haliloglu NU; Yesilirmak Z; Erden A; Erden I Dentomaxillofac Radiol; 2008 Mar; 37(3):161-6. PubMed ID: 18316508 [TBL] [Abstract][Full Text] [Related]
33. A prospective study of mucormycosis in north India: experience from a tertiary care hospital. Bala K; Chander J; Handa U; Punia RS; Attri AK Med Mycol; 2015 Apr; 53(3):248-57. PubMed ID: 25587084 [TBL] [Abstract][Full Text] [Related]
35. COVID-19-associated rhino-orbito-cerebral mucormycosis: a single center prospective study of 264 patients. Kim U; Perzia B; Kulkarni P; Rajiniganth M; Sundar B; Robin AL; Garg Shukla A; Maeng MM Orbit; 2024 Jul; ():1-10. PubMed ID: 39051497 [TBL] [Abstract][Full Text] [Related]
36. Epidemiology, clinical presentation and management of COVID-19 associated mucormycosis: A single centre experience from Pune, Western India. Dravid A; Kashiva R; Khan Z; Bande B; Memon D; Kodre A; Mane M; Pawar V; Patil D; Kalyani S; Raut P; Bapte M; Saldanha C; Chandak D; Patil T; Reddy S; Bhayani K; Suresh L; Dillibabu V; Srivastava S; Khandelwal S; More S; Shakeel A; Pawar M; Nande P; Harshe A; Kadam S; Hallikar S; Kamal N; Andrabi D; Bodhale S; Raut A; Chandrashekhar S; Raman C; Mahajan U; Joshi G; Mane D Mycoses; 2022 May; 65(5):526-540. PubMed ID: 35212032 [TBL] [Abstract][Full Text] [Related]
37. Rhino-orbito-cerebral mucormycosis infection in a 4-year-old Egyptian girl. Sorour A; Abdelrahman AS; Abdelkareem A; Kadry A; Gamal A Med Mycol Case Rep; 2022 Sep; 37():29-32. PubMed ID: 35855929 [TBL] [Abstract][Full Text] [Related]
38. Invasive rhino-orbito-cerebral mucormycosis in a diabetic patient - the need for prompt treatment. Chow V; Khan S; Balogun A; Mitchell D; Mühlschlegel FA Med Mycol Case Rep; 2015 Jun; 8():5-9. PubMed ID: 25750854 [TBL] [Abstract][Full Text] [Related]
39. COVID-19-associated rhino-orbital-cerebral mucormycosis: A systematic review, meta-analysis, and meta-regression analysis. Bhattacharyya A; Sarma P; Kaur H; Kumar S; Bhattacharyya J; Prajapat M; Prakash A; Sharma S; Reddy DH; Thota P; Bansal S; Gautam BS; Medhi B Indian J Pharmacol; 2021; 53(6):499-510. PubMed ID: 34975140 [TBL] [Abstract][Full Text] [Related]
40. Rhino-Orbital Cerebral Mucormycosis in a Diabetic Patient: An Emergency Medicine Case Report. Sweet R; Hovenden M; Harvey CE; Peterson W; Lott I J Emerg Med; 2023 Mar; 64(3):385-387. PubMed ID: 36932004 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]